Abstract：Objective To explore the diagnostic value of serum phosphorus and some tumor markers for breast cancer (BC) bone metastasis.Methods Different clinical parameters were analyzed from the medical records of 674 patients with breast cancer in this retrospective study. Their baseline data was collected, including age, weight, height, body mass index(BMI), such laboratory markers as serum phosphorus, alkalinehosphatase(ALP), TPS, CEA, Ca199, CA125, CA153, TPS, clinical stage, and pathological test.Results There was no significant difference between the two groups(t=0.768,P=0.444) before treatment. However, serum phosphorus levels were significantly lower in patients with bone metastasis(1.04±0.21)mmol/L than in those without bone metastasis(1.23±0.21)mmol/L (t=7.51, P=0.000) after treatment. Serum phosphorus levels significantly decreased in patients with bone metastasis compared with the control, but were significantly increased after treatment in the control. The same results were obtained after paired t-test.Conclusions Serum phosphorus levels are significantly lower in patients with breast cancer bone metastasis. Serum levels of ALP, CA153 and TPS may be potential diagnostic indicators for BC bone metastasis, especially in the early stage. After treatment, the level of serum phosphorus should be monitored.
杜丽莉, 荆结线, 王艳, 曹芳芳. 血磷、ALP、CA153及TPS对乳腺癌骨转移的诊断价值[J]. 武警医学, 2020, 31(1): 20-22.
DU Lili, JING Jiexian, WANG Yan,and CAO Fangfang. Clinical value of levels of serum phosphorus,ALP, CA153 and TPS for breast cancer bone metastasis. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(1): 20-22.
Goretti Pinedo M, Alon U S. Erratum to: phosphate homeostasis and its role in bone health [J]. Pediatr Nephrol, 2017, 32(10): 1999.
[2]
Dayanand P, Sandhyavenu H, Dayanand S, et al. Role of bisphosphonates in vascular calcification and bone Metabolism: a clinical summary[J].Curr Cardiol Rev, 2018, 14(3):192-199.
[3]
De Carvalho C C, Caramujo M J. Tumour metastasis as an adaptation of tumour cells to fulfil their phosphorus requirements[J].Med Hypotheses, 2012,78(5):664-667.
[4]
Kenney J M, Marinelli L D, Woodard H O. Tracer studies with radioactive phosphorus in malignant neoplastic disease [J]. Radiology, 1941, 37: 683-687.
[5]
Ferreira Poloni P, Vespoli H L, Almeida-Filho B S, et al. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study[J]. Climacteric, 2017, 20(5): 491-497.
[6]
Stratton J,Hu X,Soulos P R, et al. Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors[J], J Oncol Ract, 2017, 13(5): e505-e515.
[7]
Zain N M, Seriramulu V P, Chelliah K K. Bone mineral density and breast cancer risk factors among premenopausal and postmenopausal women: a systematic review [J]. Asian Pac J Cancer Prev, 2016, 17(7): 3229-3234.
[8]
Qu X, Zhang X, Qin A , et al. Bone mineral density and risk of breast cancer in postmenopausal women [J]. Breast Cancer Res Treat, 2013, 138 (1): 261-271.
Christensen C , Cronin-Fenton D, Frslev T, et al. Change in bone mineral density during adjuvant chemotherapy for early-stage breast cancer [J]. Support Care Cancer, 2016, 24(10):4229-4236.
[11]
Axelsen C T,Jensen A B,Jakobsen E H,et al. Bone loss during neo adjuvant/adjuvant chemotherapy for early stage breast cancer: a retrospective cohort study [J]. Mol Clin Oncol, 2018, 8(6): 767-772.
[12]
Sapio L, Naviglio S. Inorganic phosphate in the development and treatment of cancer: a Janus Bifrons?[J]. World J Clin Oncol, 2015, 6(6): 198-201.
2020, Vol. 31 
